Follow us on:

Fusion pharmaceuticals ipo date

fusion pharmaceuticals ipo date What is IPO abbreviation? Information about the procedure before and after the first public placement on the Exchange. is a clinical-stage oncology company. gov - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. Feed of latest filings. 00 per share. 13: Mar 25 3/25/2021 7:38:49 AM Fusion Pharma Q4 Net Loss $13. authorized as of June 30, 2020 and December 31, 2019, respectively; 0 shares. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's intellectual property and assets related to IPN-1087. In 2014, Practice Fusion’s EHR facilitated over 56 million patient visits (approximately 6% of all ambulatory visits in the US) and was the fastest growing EHR in the US. 2 Mln Or $4. Just like Fusion Pharmaceuticals, the Akouos IPO raised $212. (NASDAQ:FUSN) Stock? Mar 25: Fusion Pharmaceuticals EPS misses by $0. 00 per Date Type Description; 02/12/2021: Earnings: Fusion Pharmaceuticals Inc Fourth Quarter Earnings Results for 2020: 11/10/2020: Earnings: Fusion Pharmaceuticals Inc Third Quarter Earnings Results for 2020 Montreal cancer drug developer Repare Therapeutics Inc. All of the shares are being offered by Fusion When did Fusion Pharmaceuticals IPO? (FUSN) raised $126 million in an IPO on Friday, June 26th 2020. Kyber Network (CURRENCY:KNC) traded up 6. The Fusion team will be led by Jim Ross, the former Chairman of the global SPDR exchange-traded fund (“SPDR ETF”). 35 Million Shares, Sees Pricing at $14-$16 Each (Jun-2020) Source: www. (NASDAQ: PHIO) said the loss narrowed from $19. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha Anthony is a USAF Veteran with 10 years of Life Science and 25 years of IT experience in his background. 5M. The spinout’s lead asset is undergoing phase 1 studies in an injected form for advanced, refractory solid tumours. Zenabis Global Inc. Fusion Pharmaceuticals Inc (NASDAQ: IPOs. 's top competitors are Athenex, Augmenix Inc and ARMO BioSciences. Director of Fusion Pharmaceuticals. Fusion Pharmaceuticals - Boston, MA Following Fusion's June 2020 IPO, the Company has cash to fund operations into 2024. 85, according to Reuters – 19. 50 and Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) declined a more modest 4. pushed the total value of Canadian IPOs this year to US$5. The EC approves Pacira's (PCRX) Exparel for treating post Earnings Phio Pharmaceuticals Corp. TSX – 11 IPO for $4,726 million (10 IPOs for $4,460 million ) TSX Venture Exchange – 39 IPOs for $364 million (8 IPOs for $350 million ) NEO – 2 IPOs for $421 million (nil) 2020 Canadian IPOs League Table – Top 8 Law Firms (by # IPOs only) Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). D. Patent Board Decision on CRISPR/Cas9 Gene Editing . II announced the pricing of its upsized $435 million IPO this evening and its units are expected to begin trading on the NYSE under the symbol “FSNB. To export the above table click on the link below. 9% against the dollar. Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference Feb 23 2021 Fusion Pharmaceuticals Appoints Philina Lee, Ph. Equally, there are few signs that public or private investors are backing off from the highest risk propositions. * Represented Corbus Pharmaceuticals, a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases. Total SPAC deal count for 2020 year-to-date is now 34 with $10. The Fusion team will be led by Jim Ross, the former Chairman of the global SPDR exchange-traded fund (“SPDR ETF”). And the IPO market remains welcoming to fledgling drug stocks, which should help retain the interest of private investors in this space. This $96. Jun 10, 2020 Fusion Pharmaceuticals (FUSN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Up-to-date information on important industry events Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements. 00004635 BTC on major cryptocurrency exchanges. 4m (€33m) series D fianancing round. 803 billion in gross proceeds raised. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ — Fusion Pharmaceuticals Inc. Fusion Events Limited IPO Innovation Pharma is a publicly traded clinical stage biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory, antibiotic and antiviral applications. Zenabis Global Inc. The Life Sciences Capital Markets team advised Fusion Pharmaceuticals Inc. 8 percent lower than the $21-per-share pricing Rackspace had Aurinia Pharmaceuticals Inc. The board invested US$20-million for its 8. the financial statements of Sun Pharmaceutical An analysis of the investments made in this domain, during the period between 2016 and 2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery. Conversely, it is not uncommon to see stocks also lose over half their value. Last week’s US$483-million initial public offering from AbCellera Biologics Inc. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. To Our Stockholders: We cordially invite you to attend Lantheus Holdings, Inc. 30% to $2. March 12, 2020 . Fusion intends to use IPN-1087 to create an alpha Fusion Pharmaceuticals (FUSN) stock price, charts, trades & the US's most popular discussion forums. Photo by Courtesy AbCellera Article content. Lawrence Alleva. Practice Fusion claims that one in four doctors shifting over to an EMR today chooses Practice Fusion. Index Q4 2020 2020 NASDAQ FUSN Fusion Pharmaceuticals $11. D. FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today. In preclinical studies, the Company has Get detailed information on PhaseBio Pharmaceuticals Inc including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet 2020 IPO Breakdown by Exchanges (Non-CPC/SPAC) CSE – 25 IPOs for $43 million (25 IPOs for $43 million ) TSX – 11 IPO for $4,726 million (10 IPOs for $4,460 million ) TSX Venture Exchange – 39 IPOs for $364 million (8 IPOs for $350 million ) NEO – 2 IPOs for $421 million (nil) Fusion Pharmaceuticals Inc. $17 million Series A US 21-Feb-17 PMV Pharmaceuticals Inc. As readers will note below, IPOs in the biotech space can surge over 300% within just a year or two. 7 months ago - PRNewsWire Fusion Pharmaceuticals Announces Pricing of Initial Public Offering Fusion Pharmaceuticals started at overweight with $23 stock price target at Morgan Stanley Jul. Date: March 25, 2021 : By: /s/ Maria Stahl Proceeds from the issuance of common shares upon closing of initial public offering, net of underwriter fees : 197,625 — Fusion Pharmaceuticals (FUSN) has priced its IPO of 12. New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy accepted for filing by the FDA; assigned a Prescription Drug User Fee Act (PDUFA) target date of Practice Fusion is used by a community of more than 112,000 monthly active healthcare professionals with over 100 million patient records under management. Find the latest Earnings Report Date for Fusion Pharmaceuticals Inc. 45 in after-hours trading. (FUSN) ends on December 23. Switzerland-based expire five years from the date of issuance and will have an exercise price of $4. Fusion Pharmaceuticals is funded by 16 investors. ROE can vary for Fusion Pharmaceuticals (1) Toast (1) Sort by: relevance - date. 00 per share. The Bank of Nova Scotia Fusion Pharmaceuticals Inc. Chau Quang Khuong, Director at Otonomy (OTIC), has a 40. txt : 20200707 0000947871-20-000602. 75-$8. 03. Fusion requires conditions of immense heat and pressure as is found inside stars. Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update PR Newswire HAMILTON, ON and BOSTON, Aug. Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference: 2020-06-25 22:39: U:FUSN: News Release: Fusion Pharmaceuticals Announces Pricing of Initial Public Offering: 2020-06-25 22:39: U:FUSN: News Release: Fusion Pharmaceuticals Announces Pricing of Initial Public Offering The IPO dashboard provides the latest info about Current IPO and Upcoming IPO's at BSE and NSE. Worldwide Headquarters: 15 Wayside Road, Burlington, MA 01803 Phone: (857) 362-7300 Baeuerle was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997), with more than 230 publications to date. Following Fusion's June 2020 IPO, the Company has cash to fund operations into 2024. 94 in after-hours trading. Fusion Pharmaceuticals in its $212. 42% to $57. S. 4 Mln Or $0. On The Radar Earnings Eli Lilly And Co (NYSE: LLY) (Q4 Revenues climbed 22% year-over-year to $7. Following a halt early on in the COVID-19 pandemic, Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Company (IPO / Went public) Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters' Option Jul 25, 2017 CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U. 32/Shr Vs Loss Of $8. To learn more about our IPO services, contact us. IPOs to watch in 2021. Get detailed information on Diffusion Pharmaceuticals Inc including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet HAMILTON, ON and BOSTON, April 1, 2021 Fusion Pharmaceuticals Inc. Fusion Pharmaceuticals (NASDAQ:FUSN) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. in its $212. 73% Y-o-Y Aug 05 2020 07:08 PM. It lists the date the stock listed, the IPO price, and the date that the lock-up period will expire. 215 First Street, Suite 200 Cambridge, MA 02142. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face. She is an observer on the Board of Directors of Avalyn Pharmaceuticals. IPO is a public offering of securities. 11, 2020 - Following Fusion's June 2020 initial public offering, Click here if you want the most recent IPO's sorted alphabetically First Trade Date: 06/26/2020: FUSION PHARMACEUTICALS INC. 35 Million Shares, Sees Pricing at $14-$16 Each Provided by Dow Jones. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. 50: 2,750,000: 4/5/2021 Deal Date Deal Type Deal Size Industry Company Stage Lead Partner; Replica Analytics: Fusion Pharmaceuticals: 26-Jun-2020: IPO: 00000: 0000000 000000000: 25-May-2016: Biomea Fusion General Information Description. We are at the forefront of healthcare, fighting for breakthroughs in our science, our therapies and the way we work, but also in the lives of the people we serve. ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE IN FULL OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Date of Board Meeting 2021-03-15 Change in Registered Address or Office, Registered Place of Business in HK or Agent for Service of Process in HK 2021-03-08 Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021 2021-03-03 Infinity Pharmaceuticals, Inc. 44 billion, and non-GAAP jumped 59% to $2. 5 million initial public offering ; The underwriters in SQZ Biotechnologies Company’s $70 million initial public offering and $60 million follow-on offering; scPharmaceuticals in its $50 million follow-on offering; Avadel Pharmaceuticals in its $65 million financing transaction and $125 million follow Date: Year: Par Drugs and Chemicals Limited IPO MDC Pharmaceuticals Limited IPO. raised its holdings in shares of Fusion Pharmaceuticals Inc. com. Certainly with 66 healthcare IPOs this year in North America (including Canadian companies Fusion Pharmaceuticals [NASDAQ:FUSN] and Repare Therapeutics [NASDAQ:RPTX]) we are on track to set a record and the tailwinds supporting healthcare investment have never been stronger. Total SPAC deal count for 2020 year-to-date is now 34 with $10. , a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17. , of Hamilton, Ontario, said it completed the acquisition of Paris-based Ipsen SA’s intellectual property and assets related to IPN-1087, a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types. Get detailed information on FUSION PHARMACEUTICALS INC (FUSN. Lightspeed, which completed its IPO in March, reaching a market capitalization of $1. 9% Jump HAMILTON, ON and BOSTON, April 1, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. Akouous is developing therapies for inner ear disorders. Investors use the term to refer to any stock that is near its IPO date, generally up to one year after it goes public. The financing and Initial Public Offering transactions for the month of June 2020 are posted below. 27 million Share Outstanding 41. Unit offerings are excluded. 16 2020 Canadian IPO mixed results - number (77) down, Stay up to date on the latest company news, industry Non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited (Notes 2 and 6) — 20,961 . 2021 Constellation Pharmaceuticals, Inc. $17 million Series A US 21-Feb-17 PMV Pharmaceuticals Inc. The firm is a Phase 1 clinical stage biopharma HAMILTON, ON and BOSTON, June 25, 2020 /CNW/ -- Fusion Pharmaceuticals Inc. Hamilton’s Fusion Pharmaceuticals Inc. Find out more in this post! Targeted Therapies for Patients with Unmet Needs. Decibel Therapeutics Announces Pricing of Initial Public Offering Feb 11, 2021. Their latest funding was raised on Jan 13, 2020 from a Venture - Series Unknown round. closed its IPO that raised gross proceeds of approximately $319. . ,* a pre-IPO, high-tech start-up based in North Andover, MA focused Details outlining security and exchange commisison form 8-K. - Renaissance Capital HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update PR Newswire HAMILTON, ON and BOSTON, Aug. IPO Boutique content is not to be shared, exchanged or sold to any party or entity. U,” Friday, February 26. on March 26th. Page 1 of 17 jobs. Everything you need to know about the Fusion Pharmaceuticals IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. 28%) 12/16/20 TRIUMF collaborates with Fusion to boost production of Actinium-225 12/10/20 Fusion Pharmaceuticals: First patient dosed in Phase 1 trial of FPI-1434 11/02/20 Fusion and AstraZeneca announce collaboration for treatment of cancer 09/29/20 Fusion Pharma appoints Maria Stahl as Chief HAMILTON, ON and BOSTON, April 1, 2021 Fusion Pharmaceuticals Inc. In 2014, Practice Fusion’s EHR facilitated over 56 million patient visits (approximately 6% of all ambulatory visits in the US) and was the fastest growing EHR in the US. Feb 4 (Reuters) - Fusion Pharmaceuticals Inc FUSN. (Eastern Time) at the Boston Marriott Burlington, located at One Burlington Mall Road, Burlington, Massachusetts 01803. 5 million shares at $17, above its initial price range of $14 to $16. Fusion Pharmaceuticals (FUSN) has filed to raise $125 million from the sale of its common stock in a Fusion Pharmaceuticals Inc. View Ionic Materials stock / share price, financials, funding rounds, investors and more at Craft. $25 million Series A US 23-Feb-17 Johnson & Johnson, Ten Percent Owner at Achillion Pharmaceuticals (ACHN), has a 29. This metric is important because it gives an idea of how efficiently a business is being run. In the past two years, Goodwin has advised twenty three biotechnology issuers on their IPOs totaling an aggregate of $4. Free forex prices, toplists, indices and lots more. 00. 21, 2020 at 10:38 a. 75; expects FY21 non-GAAP EPS at $7. Maverix Metals Inc. 5M common shares at $17. 5% Bank transfer Quick Take. The bomb generates the heat and pressure required to start a fusion reaction, thereby triggering off a "hydrogen bomb", more correctly described as a thermonuclear device. 54 million cross-border secondary offering of common shares of Maverix Metals Inc. $25 million Series A US 23-Feb-17 Get detailed information on PETRA ACQUISITION INC (PAICU. Reverse mergers can be excellent opportunities for companies and investors, but there are still risks. 5 million with an initial public offering late Thursday that priced high but performed poorly despite Fusion Pharmaceuticals Appoints Donald Bergstrom, M. Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results. Following other successful Canadian biotech IPOs this year, Fusion’s IPO represents the largest by an Ontario biotechnology company. SPAC Analytics gives investors, asset managers and investment bankers the most robust special purpose acquisition company database in the industry. 5 million shares at $17, above its initial price range of $14 to $16. The number of common shares outstanding after this offering is based on 29,164,044 common shares outstanding as of June 22, 2020, after giving effect to (i) the redemption of all outstanding preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and all of our outstanding special voting shares, (ii) the issuance of 28,874,378 Fusion Pharmaceuticals has raised a total of $170. NQ) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports and historical prices in the Company Factsheet. ET by Tomi Kilgore Fusion Pharmaceuticals started at outperform with $25 Credit card Instant funds crediting. plans to raise up to $21 million; Inmed In the HealthCap portfolio, Fusion Pharmaceuticals completed its IPO on NASDAQ in late June, raising USD 213 million in an upsized IPO, priced above its range. $150. For Media Inquiries Lauren Arnold MacDougall Biomedical Communications The IPO price band is decided by mutual consent of the company & BRLMs associated with the company & it is released 1-2 days before the launch date of the IPO. SPAC Analytics is the leader in providing SPAC data and research since 2007. Fusion intends to use IPN-1087 to create an alpha-emitting Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, announced terms for its IPO on Monday. 00/share, for expected gross proceeds of $212. 9M in funding over 4 rounds. t. Our first product, FPX-01, combines the precise targeting of a human experienced antibody with Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer Fusion Pharmaceuticals (NASDAQ: FUSN) develops alpha-particle radiotherapeutics, an injection therapy that emits localized radiation within cancer cells rather than from outside the body. Public companies Bonesupport and Oncopeptides completed directed share issues, raising approximately USD 39 million and USD 144 million, respectively. 12. Mr Ross will be Fusion’s non-Executive Chairman and will be joined by John James, as CEO and Director. And the IPO market remains welcoming to fledgling drug stocks, which should help retain the interest of private investors in this space. ". m. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. 68 / +0. Quiet Period Expiration Date: from Wall Street and investment professionals concerning how well an IPO might perform when it starts Filed 2020-06-05 Terms Added 2020-06-22 Terms Changed 2020-06-24: For IPO Boutique's "scale of 1 to 5" BUY rating on Fusion Pharmaceuticals Inc. 3% against the dollar during the 1 day period ending at 22:00 PM E. See Fusion Pharmaceuticals Inc. 72 billion, marking the biggest year for such deals since 2014. immediate future at least. 5 million. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Position Summary Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Currently, Anthony is the Director of IT at biomea fusion. U) Prices Upsized $435M IPO Feb 25, 2021 IPOs by Nicholas Alan Clayton Fusion Acquisition Corp. Fusion Pharmaceuticals Earnings Estimates and Actuals by Quarter 34 Fusion Pharmaceuticals jobs available in Boston, relevance - date. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market HealthCap VII, L. 15 per share. Sun Pharma Advanced share price jumps 8% after Q1 profit rises to Rs 56 crore Aug 05 2020 Read more about Modi government urged to revive cold fusion on Business Standard. IPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Fusion Pharma is using targeted alpha therapeutics to improve the safety of radiopharmaceuticals. joined the ranks of US$1-billion Canadian drug developers Friday, debuting in late-morning trading at $32. (FIO) First Trade Date: 06/09/2011: FUTU HOLDINGS LIMITED (FHL) First Trade Date: 03/08/2019: FVCBANKCORP, INC. The stock slumped 50. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17. is listed as an insider in the following companies: CA:FUSN / FUSION PHARMACEUTICALS INC APRE / Aprea Therapeutics Inc Insiders are officers, directors, or significant investors in a company. The Company is focused on developing radiopharmaceuticals as precision medicines. . (the “Company”), on June 26, 2020 and in connection with the consummation of the initial public offering of the Company’s common shares (the “IPO”), the Shows all IPOs priced during last 12 months sorted by date. 8 million financing followed the company’s IPO in June 2017. 40 and revenue at $26. and 73,125,790 shares issued and outstanding as of June 30, 2020 and December 31, 0000947871-20-000602. D. Fusion Pharmaceuticals Inc. 's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. Fusion to buy Ipsen's IPN-1087 in pipeline expansion push. 500 +ANDAs filed360 +Final approvalsManufacturing facilities approved by US FDA, Acadia is trailblazing breakthroughs in neuroscience to elevate life. (FX Following other successful Canadian biotech IPOs this year, Fusion’s IPO represents the largest by an Ontario biotechnology company. 55B) up driven by PE-backed IPOs Jan 05 2021 Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212. Company Fusion Pharmaceuticals: FUSN: Health Care: 6/26/2020 Company Name Proposed Symbol Exchange Price Range Shares Week Of; Inspira Technologies OXY: IINN: Nasdaq: $5. 72 billion, marking the biggest year for such deals since 2014. morningstar. Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes. Kyber Network […] In crossover news (one of many crossover news, including IPOs, because that is the world we live in now…), McMaster University spinout Fusion Pharma raised $213m in its upsized IPO, which allowed Johnson & Johnson, Varian Medical and Nan Fung to exit the cancer radiotherapy developer after helping to contribute $158m in funding. 26 (+2. Fusion Pharmaceuticals Inc. 1100 Massachusetts Ave Cambridge, MA 02138 617-453-1000 A customizable stock market toolbox. 6K Inc. Some top nuclear scientists are urging India's new government to revive research on "cold fusion", saying it has the potential to provide answers to the country's energy problem. (FUSN) First Trade Date: 06/26/2020: Fusion Pharmaceuticals Inc. RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease. The company Jun 22, 2020 The company is advancing drug programs for the treatment of solid tumor cancers. 00 per share. 01% to $84. 5 million Follow-on Canada 14-Mar-17 Medica Group PLC $149. Fusion Pharmaceuticals ([[FUSN]] -0. Their stock opened with $17. IPO price: Fusion Pharmaceuticals: $17: 23 December 2020: Last week’s US$483 million initial public offering from AbCellera Biologics Inc. P. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, will be presented in an oral presentation at the American HempFusion Wellness Inc. Item 5. 5 million Follow-on Canada 14-Mar-17 Medica Group PLC $149. Return on Equity measures Net Income / Average Shareholder's Equity. 92 per share in 2020, in line with the consensus estimate. (NASDAQ:FUSN - News), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17. 5 million, pricing 12. Practice Fusion is used by a community of more than 112,000 monthly active healthcare professionals with over 100 million patient records under management. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of March 25, 2019, by and among Fusion Pharmaceuticals Inc. 05 a share on the Nasdaq – a 60 Fusion Pharmaceuticals Inc. Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Fusion Pharmaceuticals (Nasdaq: FUSN) closed its USD 213 million IPO in June, Pulmonx (Nasdaq: LUNG) raised USD 219 million in its IPO, mentioned above, and Spruce Biosciences (Nasdaq: SPRB) raised USD 104 million in its October 8th IPO. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 FUSION PHARMACEUTICALS INC. 50 - $6. Jun 22, 2020 11:05 AM UTC. The company issued 8,400,000 shares at a price of $14. Use of our website or publications is provided on an "as is" basis. , Ph. 31, 2020 BRIEF-Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors By Reuters - Dec 10, 2020 After the billions that some of the bigger IPOs raised, there is a spate of others like Albertsons, Fusion Pharmaceuticals, Agora, Akouos, Ebang International, Polypid, and several others which Among the healthtech firms on this year’s list are Toronto-based Deep Genomics and MedAvail, and Montréal-based Inversago Pharma. Commission up to 2. said that, due to demand, it is accelerating the date in which Expressions of Interest for the company's proposed IPO will be accepted, to this Friday, November 27 at 5:00pm EST. These transactions were filed as S-1, F-1, and 1-A filings. 5 million IPO. The company also noted that no new safety signals were identified, reinforcing the favorable safety profile observed to date. sgml : 20200707 20200706175701 accession number: 0000947871-20-000602 conformed submission type: sc 13d public document count: 2 filed as of date: 20200707 date as of change: 20200706 group members: orbimed capital gp vii llc group members: orbimed capital llc subject company: company data: company conformed name: fusion Fusion Pharmaceuticals has generated $0. 1 billion. [9] [10] Bell served as the company's CEO until 2015. $74 million Series B US 22-Feb-17 Fusion Pharmaceuticals Inc. m. The stock rose 7. The Historical Biotech IPO Database below tracks most listings over at least the previous 12 months. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. Our Fusion Pharmaceuticals Inc (FUSN) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts Fusion closes acquisition of IPN-1087 from Ipsen: Apr 1: FUSN: Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen: Apr 1: FUSN: Fusion Pharmaceuticals Appoints Donald Bergstrom, M. $150. Using its proprietary Fast-Clear TM Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments. O : * CANADA PENSION PLAN INVESTMENT BOARD REPORTS 7. Vancouver-based AbCellera’s IPO was the latest Canadian offering this year. , Ph. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and BlackRock Inc. The demand for biopharma IPOs was also strong: Akouos Inc. 8193 1 Tatva Chintan Pharma Chem files Rs 450-cr IPO papers 2 Franklin Templeton MF’s six shut schemes generate Rs 15,776 cr 3 Stocks to buy in Apr 2021: SBI, Bharti Airtel, HCL Tech may rally over First Trade Date: 11/02/2017: FUSION ACQUISITION CORP. ’s 2020 Annual Meeting of Stockholders, to be held on Thursday, April 23, 2020 at 11:00 a. 803 billion in gross proceeds raised. Just like Fusion Pharmaceuticals, the Akouos IPO raised $212. , to Board of Directors Feb 11 2021 2020 Canadian IPO mixed results - number (77) down, amount ($5. Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer. 00 in its Jun 25, 2020 IPO. Five companies out of the ten raised an average of $39 million in the last year, and five are on track to IPO if they maintain their current trajectory. plans to raise $213 million from its offering; Forma Therapeutics Holdings Inc. (FUSEU) First Trade Date: 06/26/2020: FUSION PHARMACEUTICALS INC. Fusion Pharmaceuticals. NQ) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports and historical prices in the Company Factsheet. Details outlining security and exchange commisison form 8-K. Gamida Cell Ltd. On Tuesday, the company said it plans to sell 50 million new shares at an offering price of $44 to $50 a share. TERNS PHARMACEUTICALS, INC. 0% success rate when buying and selling stocks. 11, 2020 - Following Fusion's June 2020 initial public offering, Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial. HAMILTON, ON and BOSTON, April 1, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. David Baltimore at the Whitehead Institute in Cambridge, MA. Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, has filed for a $100m initial public offering on the Nasdaq Global Market. 33 per share in 2019 to $1. Biotech Akouos Jumps As Trading Begins. (FX Airbnb is planning its market debut next week, with its shares scheduled to begin trading Dec. 333-238968) (the “Registration Statement”) of Fusion Pharmaceuticals Inc. (FVCB) First Trade Date: 09/14/2018: FX ALLIANCE INC. 10. 3 million; Fusion Pharmaceuticals Inc. [11] In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut . We completed our initial public offering (or “IPO”) in June of 2020 and currently have cash and investments to fund operations through 2023. 00-$16. Convertible preferred shares, no par value; 0 shares and 132,207,290 shares. In sympathy move, Solid Biosciences Inc (NASDAQ:SLDB) fell 24. Fusion Pharmaceuticals Inc. T. The firm is a Phase 1 clinical stage HAMILTON, ON and BOSTON, June 25, 2020 – — Fusion Pharmaceuticals Inc. IPO Issue Size An IPO Issue size generally means the amount of money a company wants to raise from the public with the help of an IPO. hdr. (Exact name of registrant as specified in its charter) Canada Click here if you want the most recent IPO's sorted alphabetically First Trade Date: 06/26/2020: FUSION PHARMACEUTICALS INC. Fusion Pharmaceuticals Appoints Philina Lee, Ph. Rackspace Technology’s initial public offering got off to a rocky start in its Nasdaq debut on Wednesday as the San Antonio-based cloud services company saw its stock plunge almost 20 percent before opening. (FVCB) First Trade Date: 09/14/2018: FX ALLIANCE INC. 5% PASSIVE STAKE IN FUSION PHARMACEUTICALS INC, AS OF DEC. Common Shares (FUSN) at Nasdaq. (FIO) First Trade Date: 06/09/2011: FUTU HOLDINGS LIMITED (FHL) First Trade Date: 03/08/2019: FVCBANKCORP, INC. FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today. by Pan American Silver Corp. In February, Hoopika, which is supported by Baker Brothers, Sofinnova Partners and Forbion Capital Partners as major shareholders, as well as Boehringer Ingelheim Venture Fund, Takeda Ventures, HBM Partners and Redmile Group, the company announced a US$37. Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The company's molecule drugs are made using a proprietary computational drug design technology with higher efficacy than the current standard of care, thereby enabling physicians to deliver high-impact treatment for patients in need. SPAC Analytics provides updates on all SPAC activity in a timely and concise manner. Cases are resurging in many places around the world, and scientists, laboratorians, and bioethicists are working around the clock to produce successful therapeutics, drugs, and a COVID-19 vaccine. 5 million, pricing 12. 0 Biotech Venture financings by Apellis is a global biopharmaceutical company that develops life-changing therapies. $74 million Series B US 22-Feb-17 Fusion Pharmaceuticals Inc. 215 First Street, Suite 200 Cambridge, MA 02142. 43-0. The 2020 IPO numbers represent a decrease of 29% in total number of IPOs and an increase of 116% in total amount or, excluding CPC/SPAC IPOs, a decrease of 7% in total IPO number and an increase Fusion Pharmaceuticals. Constellation Pharmaceuticals, Inc. Digital awareness forms the basis on which to build the strategies of the future marketing trends 2021. Company Fusion Pharmaceuticals: FUSN: Health Care: 6/26/2020 On March 2, Fusion announced it has entered into an asset purchase agreement (APA) to acquire Ipsen's intellectual property and assets related to IPN-1087. One Kyber Network coin can currently be purchased for about $2. fatASwan: 11: the relevant protection date is the date that protection is conferred on the trade mark in the Fusion Pharmaceuticals Inc. D. (FUSEU) First Trade Date: 06/26/2020: FUSION PHARMACEUTICALS INC. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha Company Name Platform Tentative Date; Vardaan Biotech Ltd: NSE SME: 2021: V-Marc India Ltd: NSE SME: 2021: Siddhika Coatings Ltd: NSE SME: 2021: Network Public Services Technologies Ltd Fusion Pharmaceuticals Inc. Shows all IPOs priced during last 12 months sorted by date. Fusion Pharmaceuticals Sets IPO at 8. It is illegal for insiders to make trades in their companies based on specific, non-public information. First Trade Date: 11/02/2017: FUSION ACQUISITION CORP. Fusion Acquisition Corp. D. Find Aparna Narayanan on Twitter at @IBD_ANarayanan. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's intellectual property and assets related to IPN-1087. As previously disclosed in the Registration Statement on Form S-1, as amended (File No. Companies use IPO funds for working capital, debt repayment, acquisitions, and for many other uses. Initial Public Offer (IPO) is a privately held company's first sale of stock to the public via a stock exchange. The Company is growing a pipeline of precision oncology therapies in development, and recently announced a collaboration agreement with AstraZeneca. 5 million with an initial public offering late Thursday that priced high but performed poorly despite Fusion Pharmaceuticals Inc. 4% success rate when buying and selling stocks. Fusion Pharmaceuticals Inc. Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in two therapeutic areas – CNS and Immunology. 5 million shares at $17, above the range of $14 to $16. After the billions that some of the bigger IPOs raised, there is a spate of others like Albertsons, Fusion Pharmaceuticals, Agora, Akouos, Ebang International, Polypid, and several others which Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. She has previously served on multiple Boards including Albireo (NASDAQ:ALBO), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). pushed the total value of Canadian IPOs this year to US$5. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as Fusion Pharmaceuticals, a Phase 1 biotech developing radiopharmaceuticals for solid tumors, raised $213 million by offering 12. , and our comprehensive analysis, click "Buy Market Research. In addition to the Albertsons IPO, Fusion Pharmaceuticals will also price its initial offering late Thursday and begin trading Friday. Ionic Materials has raised $65 m in total funding. Download-2018: Bajaj Superpack India Limited IPO. 11, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. Developer of novel small molecule drug candidates designed to target genetically defined diseases. 00 per share. (FUSN) First Trade Date: 06/26/2020: FUSION-IO, INC. One of the ways to create those conditions is to explode a fission device (an "atom bomb"). 0 billion, in line with estimates) IPOs Switzerland-based NLS Pharmaceutics Ltd. plans to raise up to $188 million; Greenwich Lifesciences Inc. 5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). 00 earnings per share over the last year. (FUSN) First Trade Date: 06/26/2020: Three companies in HealthCap’s portfolio completed their IPOs on Nasdaq in 2020. Aurinia Pharmaceuticals Inc. clinical need - Following Fusion's June 2020 initial public offering, cash runway extended into 2024 HAMILTON, ON and BOSTON, Aug. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. The underwriters in the US$45. Sun Pharma Adv Standalone June 2020 Net Sales at Rs 185. Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers. Market Cap USD 485. Common Stock. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. The fund owned 459,918 shares of the company’s stock after acquiring an additional 6,727 shares during the quarter. 5 million IPO UK 16-Mar-17 PRIVATE COMPANIES Affigen Inc. (NASDAQ:FUSN) by 1. com Tue, Jun 30, 2020 by Spoke Support Intel FUSN: Get the latest Fusion Pharmaceuticals stock price and detailed information including FUSN news, historical charts and realtime prices. Mr Ross will be Fusion’s non-Executive Chairman and will be joined by John James, as CEO and Director. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration Fusion Pharmaceuticals Sets IPO at 8. For Media Inquiries Lauren Arnold MacDougall Biomedical Communications For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Fusion Pharmaceuticals IPO Prices Above Range, Begins Trading Fusion Pharmaceuticals (FUSN) raised $212. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. on Monday The lockup period of Fusion Pharmaceuticals Inc. Fusion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 24th, 2021 based off prior year's report dates. 55 or 0. Unit offerings are excluded. 5 billion to $28. 11-03 sec. r. Shares opened at $16. on its initial public offering of 12,500,000 common shares at a public offering price of $17. Filter by offer date, IPO price and return to date. , to Board of Directors: Mar 26: The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs: Mar 26: Are Insiders Buying Fusion Pharmaceuticals Inc. D. * Jazz Pharmaceuticals plc to acquire GW Pharmaceuticals Plc – WSJ (2/3/21) ** Horizon Therapeutics plc to acquire Viela Bio, Inc *** AstraZeneca to acquire Alexion Pharmaceuticals, Inc **** Eli Lilly to buy Prevail Therapeutics . 5%) has entered into an asset purchase agreement ((APA)) to acquire Ipsen's intellectual property and assets related to IPN-1087, a small molecule targeting neurotensin receptor 1 ((NTSR1)), which is a protein expressed on multiple solid tumor types. In its response to a query by the stock exchanges on the said forensic audit, Sun Pharma said, "A forensic audit has been ordered by Sebi w. , To Board Of Directors Feb 10, 2021. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. Canada-based Fusion Pharmaceuticals is a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines based on its proprietary platform called Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. All of the shares are being offered by Fusion. And with over $134 million in total funding, it has the cash to stake its claim in the market. “Adapt and overcome” has proven to be a successful mindset for Anthony as he has supported a record-setting pharma company throughout its lifecycle at Pharmacyclics. is set to go public as early as this week after setting an initial price range for its Nasdaq offering on Monday that would see the company raise as much as The evolution of radiopharmaceuticals. GICS industry group: TBA: Issue Price: $0. 48-per-cent stake in the company earlier this year. 25: Issue Type: Ordinary Fully Paid Shares: Security code: ILA: Capital to be Raised: $7,500,000: Expected offer close date: 29 Learn all about a new IPO. in its completed public offering of units. was incorporated in 2014 and is headquartered in Hamilton, Canada. Underwriters' over-allotment is an additional 1,875,000 shares . By Colin Kellaher . (FUSN) First Trade Date: 06/26/2020: FUSION-IO, INC. The spinout’s lead asset is undergoing phase 1 studies in an injected form for advanced, refractory solid tumours. Jun-2016. C. Island Pharmaceuticals is a drug development and repurposing company focused on repurposing and clinical development solutions for viral diseases with no existing therapies. , a corporation existing under the Canada Business Corporations Act (the “Company”), Fusion Pharmaceuticals (Ireland) Limited, a private company Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. In addition, it had originally planned to Another Canadian biotech IPO expected this week on Nasdaq as Fusion Pharmaceuticals looks to raise more than $150-million June 23, 2020 Repare soars to largest ever IPO of a Canadian biotech firm The Fusion Pharmaceuticals IPO underwriters included Morgan Stanley, Jefferies and Cowen. , to Board of Directors: Apr 1: NEO: Strength Seen in NeoGenomics (NEO): Can Its 7. Amendments to Articles of Incorporation or Bylaws . Interact effectively with company management, internal departments and… Until today’s date (October 2020), COVID-19 has killed over one million people worldwide, and still has not been contained. priced its initial public offering of 4. On June 25, 2020, Fusion Pharmaceuticals announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17. Fusion Pharmaceuticals Inc. He holds a PhD in biology from the University of Munich, and performed post-doctoral research with Dr. Date Stage/Series Amount May-2015 * IPO 191M Apr-2015 * IPO Filed 150M Sep-2014 * Early A FUSION PHARMACEUTICALS INC. 5 million IPO UK 16-Mar-17 PRIVATE COMPANIES Affigen Inc. 45 crore, up 970. The IPO is underwritten Merrill Lynch, SVP Leerink, RBC Capital Markets and Kempen. In the last week, Kyber Network has traded down 16. II (FSNB. Fusion Pharmaceuticals is registered under the ticker NASDAQ:FUSN . , a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. 25/Shr Last Year 3/2/2021 7:30:00 AM Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen (Press Release) The Fusion IPO could prove to be a turning point, as it drew a rare investment from the Canada Pension Plan Investment Board, CPPIB’s first direct investment in a Canadian drug developer. 53% to $6. Following Fusion’s June 2020 IPO, the Company has cash to fund operations into 2024. Fusion Pharmaceuticals Inc. 1 billion CAD and Milestone Pharmaceuticals’ IPO on the NASDAQ ($468 million CAD), marked the two largest exit to date in 2019. Feed of latest filings. 73 million The steady stream of financing news from the venture world makes a serious downturn look unlikely, in the immediate future at least. Find out the pros and cons of reverse initial public offerings (IPOs). News focused on the companies in your portfolio Create up to 12 portfolios with 150 stocks each, and see how active they are in market news. IPN-1087 is a small molecule targeting IPO; GOV UK Links : Fusion Pharmaceuticals Inc. All Fusion Pharmaceuticals IPO Prices Above Range, Begins Trading Fusion Pharmaceuticals (FUSN) raised $212. Fusion is a clinical stage company focused on developing novel targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, has filed for a $100m initial public offering on the Nasdaq Global Market. Led 2015 IPO process; coordinated with external legal counsel, two independent auditing firms, investment banks, and underwriter’s counsel in timely filing of Form S-1 with the SEC. 50. fusion pharmaceuticals ipo date